High-Dose Wegovy Wins FDA Approval
(MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose — three times the strength…
Lilly’s Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes
INDIANAPOLIS, March 19, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational…
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.
Novo wins FDA approval for high-dose Wegovy under commissioner’s voucher
The FDA approved a high-dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to a voucher received from the commissioner’s program.
Thursday’s approval is …
STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.
Study: GLP-1RAs associated with less risk of mental illness getting worse
In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).
Triple crown: T2D purse for Lilly’s phase III retatrutide?
Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in type 2 diabetes (T2D).
Lilly’s triple-G lags Mounjaro on blood sugar lowering, first Phase 3 diabetes data suggest
Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.
The …
Ozempic Is About to Go Generic in India, China and Canada
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
GLP-1 diabetes drugs could stop anxiety and depression worsening, study finds
Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors sayDiabetes drugs could prevent anxiety and depression from worsening, according to research.Type 2 diabetes affects more than 800 million people globally and research shows that those with the condition are about twice as likely to have depression as the wider population. Continue reading…